RALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the company will participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress taking place September 3-6, 2022, in Vienna.
9 Meters will have an in-person exhibit located at booth #9 in the exhibition hall at the Messe Wien Exhibition & Congress Center. Representatives of the Company will be present on site to address medical questions on the Company's product pipeline, particularly vurolenatide for short bowel syndrome (SBS). 9 Meters recently reported positive preliminary Phase 2 results for vurolenatide in SBS, a rare disease in which patients are incapable of maintaining proper nutrition and hydration through normal oral intake alone due to a physical or functional loss of a portion of the intestines. In addition to exhibiting, 9 Meters will also be sponsoring the ESPEN event.
"We look forward to attending ESPEN in person this year and connecting with healthcare professionals focusing on clinical nutrition and its role in certain GI disorders including SBS," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "We are excited to be available to share information about our product pipeline with those attending the Congress."
About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. 9 Meters is developing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for SBS; larazotide, a tight junction regulator for MIS-C; and several near clinical-stage assets.
For more information please visit www.9meters.com or follow 9 Meters on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release includes forward-looking statements based upon 9 Meters' current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones, and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to our ability to successfully implement our strategic plans, including reliance on our lead product candidate; uncertainties associated with the clinical development and regulatory approval of product candidates, including reliance on blinded data; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the inability of 9 Meters to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs, including in light of current stock market conditions; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; risks related to leveraging the Company by borrowing money under the debt facility and compliance with its terms; risk of delisting from Nasdaq; reliance on collaborators; reliance on research and development partners; risks related to cybersecurity and data privacy; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in 9 Meters' Annual Report on Form 10-K for the year ended December 31, 2021, as amended or supplemented by our Quarterly Reports on Form 10-Q and in other filings that 9 Meters has made and future filings 9 Meters will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. 9 Meters expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Corporate Contact:
Al Medwar
SVP, Investor Relations & Corporate Communications
9 Meters Biopharma, Inc.
[email protected]
Media Contact:
Veronica Eames
LifeSci Communications, LLC
[email protected]
203-942-4626
SOURCE: 9 Meters Biopharma, Inc.